GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
GO:0048872 | Colorectum | AD | homeostasis of number of cells | 87/3918 | 272/18723 | 1.16e-05 | 2.61e-04 | 87 |
GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
GO:0043547 | Colorectum | AD | positive regulation of GTPase activity | 75/3918 | 255/18723 | 7.95e-04 | 7.91e-03 | 75 |
GO:0001782 | Colorectum | AD | B cell homeostasis | 13/3918 | 31/18723 | 6.53e-03 | 4.06e-02 | 13 |
GO:0120034 | Colorectum | AD | positive regulation of plasma membrane bounded cell projection assembly | 33/3918 | 105/18723 | 7.49e-03 | 4.55e-02 | 33 |
GO:0120032 | Colorectum | AD | regulation of plasma membrane bounded cell projection assembly | 53/3918 | 186/18723 | 8.51e-03 | 4.97e-02 | 53 |
GO:00430872 | Colorectum | MSS | regulation of GTPase activity | 101/3467 | 348/18723 | 1.00e-06 | 3.46e-05 | 101 |
GO:00488722 | Colorectum | MSS | homeostasis of number of cells | 82/3467 | 272/18723 | 2.02e-06 | 6.28e-05 | 82 |
GO:00313462 | Colorectum | MSS | positive regulation of cell projection organization | 96/3467 | 353/18723 | 3.44e-05 | 6.70e-04 | 96 |
GO:00435471 | Colorectum | MSS | positive regulation of GTPase activity | 68/3467 | 255/18723 | 7.97e-04 | 8.38e-03 | 68 |
GO:01200322 | Colorectum | MSS | regulation of plasma membrane bounded cell projection assembly | 51/3467 | 186/18723 | 1.78e-03 | 1.58e-02 | 51 |
GO:00604911 | Colorectum | MSS | regulation of cell projection assembly | 51/3467 | 188/18723 | 2.28e-03 | 1.87e-02 | 51 |
GO:00017821 | Colorectum | MSS | B cell homeostasis | 12/3467 | 31/18723 | 6.80e-03 | 4.39e-02 | 12 |
GO:01200341 | Colorectum | MSS | positive regulation of plasma membrane bounded cell projection assembly | 30/3467 | 105/18723 | 7.74e-03 | 4.84e-02 | 30 |
GO:00430873 | Colorectum | FAP | regulation of GTPase activity | 85/2622 | 348/18723 | 1.20e-07 | 7.68e-06 | 85 |
GO:00313463 | Colorectum | FAP | positive regulation of cell projection organization | 82/2622 | 353/18723 | 1.78e-06 | 7.35e-05 | 82 |
GO:00435472 | Colorectum | FAP | positive regulation of GTPase activity | 61/2622 | 255/18723 | 1.39e-05 | 3.73e-04 | 61 |
GO:00488724 | Colorectum | FAP | homeostasis of number of cells | 60/2622 | 272/18723 | 1.91e-04 | 2.79e-03 | 60 |
GO:1903131 | Colorectum | FAP | mononuclear cell differentiation | 79/2622 | 426/18723 | 5.00e-03 | 3.33e-02 | 79 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DOCK11 | SNV | Missense_Mutation | | c.710N>A | p.Arg237His | p.R237H | Q5JSL3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
DOCK11 | SNV | Missense_Mutation | | c.5804N>T | p.Ser1935Phe | p.S1935F | Q5JSL3 | protein_coding | tolerated(0.18) | possibly_damaging(0.637) | TCGA-D8-A1JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
DOCK11 | SNV | Missense_Mutation | | c.470C>T | p.Ser157Phe | p.S157F | Q5JSL3 | protein_coding | deleterious(0.02) | possibly_damaging(0.498) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
DOCK11 | SNV | Missense_Mutation | | c.6184G>A | p.Asp2062Asn | p.D2062N | Q5JSL3 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
DOCK11 | SNV | Missense_Mutation | | c.2935N>C | p.Glu979Gln | p.E979Q | Q5JSL3 | protein_coding | deleterious(0.05) | possibly_damaging(0.446) | TCGA-E9-A243-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
DOCK11 | SNV | Missense_Mutation | rs139362247 | c.4711N>T | p.Ala1571Ser | p.A1571S | Q5JSL3 | protein_coding | tolerated(1) | benign(0) | TCGA-E9-A243-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
DOCK11 | SNV | Missense_Mutation | novel | c.5266A>C | p.Lys1756Gln | p.K1756Q | Q5JSL3 | protein_coding | deleterious(0.04) | benign(0.028) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DOCK11 | SNV | Missense_Mutation | | c.3917N>T | p.Ser1306Leu | p.S1306L | Q5JSL3 | protein_coding | tolerated(0.1) | benign(0.313) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DOCK11 | SNV | Missense_Mutation | | c.4331T>C | p.Leu1444Pro | p.L1444P | Q5JSL3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | CR |
DOCK11 | SNV | Missense_Mutation | novel | c.6200C>A | p.Ser2067Tyr | p.S2067Y | Q5JSL3 | protein_coding | tolerated_low_confidence(0.08) | benign(0.015) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |